Susquehanna Fundamental Investments’s INmune Bio INMB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,473	Closed	-$127K	–	1600
2021 Q4	$127K	Sell	12,473 -4,727	-27%	-$70K	﹤0.01%	1310
2021 Q3	$334K	Buy	+17,200	New	+$332K	0.01%	1368
2021 Q2	–	Sell	-13,663	Closed	-$162K	–	1709
2021 Q1	$162K	Buy	13,663 +129	+1%	+$2.32K	﹤0.01%	1418
2020 Q4	$233K	Sell	13,534 -12,766	-49%	-$120K	﹤0.01%	1331
2020 Q3	$271K	Buy	+26,300	New	+$268K	0.01%	1094

Other funds holding INMB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna Fundamental Investments's INMB Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of INmune Bio (INMB) in Q1 2022, closing a stake of 12,473 shares — an estimated $127K sold.

Susquehanna Fundamental Investments first reported a position in INMB in Q3 2020 and held it in 5 quarters. The position peaked at $334K in Q3 2021. 34 funds tracked by Wall St. Rank hold INMB as of Q1 2022.

Susquehanna Fundamental Investments reported no remaining INmune Bio position as of Q1 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 12,473 INmune Bio shares in Q1 2022, an estimated $127K.
Susquehanna Fundamental Investments first reported a position in INmune Bio in Q3 2020 and held it in 5 quarters.
Susquehanna Fundamental Investments's INmune Bio position peaked at $334K in Q3 2021.
34 funds tracked by Wall St. Rank held INmune Bio as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.